Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Part of paid clinical trials in Detroit, Michigan.
- Sponsor
- Henry Ford Health System
- Study ID
- NCT05509933
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Engraftment Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Budesonide — DRUGbudesonide starting day 5 after transplant
Study Details
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Key Dates
- Start date
- Nov 9, 2022
- Status verified
- Apr 2026
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2027
Study Design
- Enrollment
- 110 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: Budesonide
- No Intervention: nothing
Primary Outcome Measure
non-infectious fever [ Time Frame: 30 days post stem cell transplant ]
Central Contacts
- shatha farhan3137133910
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Henry Ford Health System | Detroit | Michigan | 48202 |
Find similar trials in Detroit, MI
By research site